Opendata, web and dolomites

BRIGHT

40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BRIGHT project word cloud

Explore the words cloud of the BRIGHT project. It provides you a very rough idea of what is the project "BRIGHT" about.

route    company    promotes    accentuates    players    frequency    dementia    minimizing    intervention    invasive    prior    brain    demonstration    cascade    bright    optoceutics    variants    vital    representing    maturation    business    serving    delay    appear    liaise    accumulation    damage    drugs    market    protected    improvements    members    primarily    clinical    roll    leverage    colour    believe    optimal    inducing    beta    appropriate    ing    global    productization    blue    alone    wavelengths    while    cortex    visual    setup    white    neurodegenerative    coloured    disease    devised    capturing    formed    irreversible    stages    100bn    receptors    reduce    fusion    fadigue    prepare    ahead    untap    amyloid    experiencing    de    stimulate    light    ad    decades    protective    stepping    sizeable    combinations    core    33    later    patients    triggers    patent    prevalence    clearance    shows    pandemic    significantly    strategy    risk    approximately    certification    roadblocks    instead    industrial    full    colours    alternating    onset    led    savings    avoiding    flashing    leds    hz    alzheimer    flickering    stroboscopic    human    neuro    off    stone    founding   

Project "BRIGHT" data sheet

The following table provides information about the project.

Coordinator
OPTOCEUTICS APS 

Organization address
address: DIPLOMVEJ 381
city: KONGENS LYNGBY
postcode: 2800
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.optoceutics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OPTOCEUTICS APS DK (KONGENS LYNGBY) coordinator 50˙000.00

Map

 Project objective

While Alzheimer’s Disease (AD) is a global pandemic, it has been estimated that a five-year delay in the disease onset could reduce the disease prevalence – and its costs – by up to 33% over the next decades, representing potential savings over €100bn in EU alone. However, there are still significant roadblocks ahead as current drugs do not untap sizeable improvements in AD patients. This is primarily due to the challenge of minimizing the impact of irreversible brain damage in later dementia stages, which accentuates the need for early intervention. However, recent evidence shows that non-invasive flashing (stroboscopic) light at the appropriate frequency (40 Hz) promotes clearance of beta-amyloid – whose accumulation is believe to be one of the key triggers to the neurodegenerative cascade leading to dementia states.

Instead of using fadigue-inducing stroboscopic flashing light (i.e. on-off), the founding members of OptoCeutics have devised a unique, patent-protected method to stimulate the human visual receptors and processing cortex through alternating white light composed of different wavelengths. The two variants of the white light are formed by different combinations of coloured LEDs. When flickering between the two LED sets, the colours fusion together and appear as one, resulting in approximately the same white colour, avoiding experiencing light flashing, but the brain is capturing the blue component flashing with 40 Hz – thus still promoting neuro-protective beta-amyloid clearance.

OptoCeutics will leverage from BRIGHT as a vital stepping stone to prepare the company’s business strategy, serving also to significantly de-risk its route-to-market by enabling to liaise with major industrial and clinical players to define both the optimal productization and maturation of Optoceutics core technology, as well as the setup for its full-scale demonstration and certification, prior market roll-out.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BRIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

SmartDegrees (2020)

First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchain

Read More